315 related articles for article (PubMed ID: 14677113)
1. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
2. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M
Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of protection from graft-versus-host disease mortality by IL-2. III. Early reductions in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population.
Abraham VS; Sachs DH; Sykes M
J Immunol; 1992 Jun; 148(12):3746-52. PubMed ID: 1534824
[TBL] [Abstract][Full Text] [Related]
4. The effect of T cell depletion from spleen cell allografts on graft-versus-host disease and long-term immune reconstitution in H-2 haplotype-identical murine combinations.
Tokuda N; Mayumi H; Sakumoto M; Himeno K; Tomita Y; Nomoto K
Immunobiology; 1989 Oct; 179(4-5):328-41. PubMed ID: 2515151
[TBL] [Abstract][Full Text] [Related]
5. Long-term immunologic tolerance induction in chimeric mice after bone marrow transplantation across major histocompatibility barriers: persistent or redeveloping immunologic responsiveness after prolonged survival.
Sugiura K; Yasumizu R; Iwai H; Inaba MM; Toki J; Ogura M; Hara I; Good RA; Ikehara S
Thymus; 1991 Nov; 18(3):137-53. PubMed ID: 1838450
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of various T cell subtypes on GVHD in a murine model for MHC-matched unrelated donor transplant.
OKunewick JP; Kociban DL; Buffo MJ
Bone Marrow Transplant; 1990 Mar; 5(3):145-52. PubMed ID: 1691938
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of established graft-versus-host disease induced across the major histocompatibility barrier.
Vallera DA; Schmidberger H; Buchsbaum DJ; Everson P; Snover DC; Blazar BR
Cancer Res; 1991 Apr; 51(7):1891-7. PubMed ID: 2004372
[TBL] [Abstract][Full Text] [Related]
8. Experimental and clinical gnotobiotics: influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation.
Heidt PJ; Vossen JM
J Med; 1992; 23(3-4):161-73. PubMed ID: 1479298
[TBL] [Abstract][Full Text] [Related]
9. Alloengraftment in IL-2-treated mice.
Sykes M; Pearson DA
Bone Marrow Transplant; 1992 Aug; 10(2):157-63. PubMed ID: 1525605
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of the anti-GVHD effect of IL-2. I. Protective host-type cell populations are not induced by IL-2 treatment alone.
Abraham VS; Sykes M
Bone Marrow Transplant; 1991; 7 Suppl 1():29-32. PubMed ID: 2043882
[TBL] [Abstract][Full Text] [Related]
11. Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens.
Korngold R; Wettstein PJ
J Immunol; 1990 Dec; 145(12):4079-88. PubMed ID: 2258608
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo spermine dialdehyde treatment prevents lethal GVHD in a murine bone marrow transplantation model.
Wang E; Conant JM; Li D; Visconti V; Chourmouzis E; Lau C
Bone Marrow Transplant; 1990 Oct; 6(4):235-42. PubMed ID: 2085697
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of T cell activation in acute and chronic forms of murine graft-versus-host disease.
Via CS
J Immunol; 1991 Apr; 146(8):2603-9. PubMed ID: 2016521
[TBL] [Abstract][Full Text] [Related]
14. Immune dysfunction associated with graft-vs-host reaction in mice transplanted across minor histocompatibility barriers. II. Reversible defect in T-dependent antibody responses.
Budhecha S; Hamilton BL
J Immunol; 1989 Jun; 142(11):3740-5. PubMed ID: 2523932
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow transplantation across major histocompatibility barriers in rabbits. I. A positive role for graft-versus-host reactivity in engraftment.
Adler LT; Annaratone LJ; LeBeau MM
Bone Marrow Transplant; 1990 Jan; 5(1):51-6. PubMed ID: 2297590
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of graft-versus-host disease directed to minor histocompatibility antigens.
Korngold R
Bone Marrow Transplant; 1991; 7 Suppl 1():38-41. PubMed ID: 2043884
[TBL] [Abstract][Full Text] [Related]
17. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation.
Champlin R
Hematol Oncol Clin North Am; 1990 Jun; 4(3):687-98. PubMed ID: 2193019
[TBL] [Abstract][Full Text] [Related]
18. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo.
Johnson BD; Truitt RL
Transplantation; 1992 Jul; 54(1):104-12. PubMed ID: 1631918
[TBL] [Abstract][Full Text] [Related]
19. What determines who develops graft-versus-host disease: the graft or the host (or both)?
Gale RP; Horowitz MM; Butturini A; Barrett AJ; Kolb HJ
Bone Marrow Transplant; 1992 Aug; 10(2):99-102. PubMed ID: 1525613
[TBL] [Abstract][Full Text] [Related]
20. Antilymphocytic antibodies and bone marrow transplantation. XI. Evidence that reduced Thy-1 expression in Thy-1.1 mice prevents suppression of graft-versus-host disease with anti-Thy-1 monoclonal antibodies.
Mysliwietz J; Thierfelder S; Hoffmann-Fezer G; Kummer U
Transplantation; 1990 Apr; 49(4):749-55. PubMed ID: 1970200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
